SCHEMBL328156

SCHEMBL328156

C=C/C=C(N)\C=C/C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13593651 0.74
SCHEMBL10198751 0.74
SCHEMBL13515547 0.74
SCHEMBL13552294 0.74
SCHEMBL13392173 0.74
SCHEMBL20003584 0.74
SCHEMBL24565091 0.72
SCHEMBL18570000 0.72
SCHEMBL25088763 0.72
SCHEMBL12352915 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed
US-20230363255-A1 CONDENSED CYCLIC COMPOUND, ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME, AND ELECTRONIC APPARATUS INCLUDING THE ORGANIC LIGHT-EMITTING DEVICE SAMSUNG DISPLAY CO., LTD. (KR) 2023-11-09 US disclosed
US-11777098-B2 Method and system for functional conductive polymer initiated cathode electrolyte interface for silicon anode-based lithium ion batteries ENEVATE CORPORATION (US) 2023-10-03 US disclosed
EP-4225006-A2 ORGANIC LIGHT-EMITTING DEVICE Samsung Display Co., Ltd. (KR) 2023-08-09 EP disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
EP-4199127-A1 ORGANIC LIGHT-EMITTING DEVICE AND COMPOSITION FOR FORMING ORGANIC MATERIAL LAYER LT Materials Co., Ltd. (KR) 2023-06-21 EP disclosed
US-20220006020-A1 DI-, TRI- AND TETRAPHENYLINDANE DERIVATES AND THEIR USE IN ORGANIC ELECTRONICS DOTTIKON ES HOLDING AG (CH) 2022-01-06 US disclosed
US-10954199-B2 Process methods for phosphatidylinositol 3-kinase inhibitors GILEAD SCIENCES, INC. (US) 2021-03-23 US disclosed
WO-2021022076-A1 MOLECULES AND METHODS RELATED TO TREATMENT OF UNCONTROLLED CELLULAR PROLIFERATION ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2021-02-04 WO disclosed
US-10881608-B2 Biodegradable intravitreal tyrosine kinase implants ALLERGAN, INC. (US) 2021-01-05 US disclosed
US-8426433-B2 Anticoagulant compounds, pharmaceutical compositions on their basis to treat thrombotic conditions, and plasma-substituting solution to correct hypercoagulation defects of hemodilution Obschestvo S Ogranichennoi Otvetsttvennoctiyu “Bionika” (RU) 2013-04-23 US disclosed
WO-2013053969-A1 HAPTENS, CONJUGATES AND ANTIBODIES FOR THE FUNGICIDE CYPRODINIL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC) (ES) 2013-04-18 WO disclosed
EP-2532655-A1 AMINOANTHRACENE DERIVATIVE AND ORGANIC ELECTROLUMINESCENT ELEMENT FORMED USING SAME Idemitsu Kosan Co., Ltd. (JP) 2012-12-12 EP disclosed
WO-2012136859-A1 MEDICAMENT FOR LIVER REGENERATION AND FOR TREATMENT OF LIVER FAILURE Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2012-10-11 WO disclosed
WO-2012032014-A1 ETHYNE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-03-15 WO disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 EP disclosed
EP-1615613-B1 QUINOXALINYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARM INC (US) 2009-11-04 EP disclosed
EP-1927604-A1 Functional monomers for molecular recognition and catalysis MIP Technologies AB (SE) 2008-06-04 EP disclosed
EP-1070990-B1 Lithographic printing plate precursor and method of making lithographic printing plate FUJIFILM CORP (JP) 2007-04-25 EP disclosed
WO-2006040650-A1 4-METHOXYACRIDINE-1-CARBOXAMIDE DERIVATIVES AND THE PHENAZINE AND OXANTHRENE ANALOGS AS PDE4-INHIBITORS FOR THE TREATMENT OF ASTHMA AND CHRONIC PULMONARY DISEASE (COPD) GLENMARK PHARMACEUTICALS S.A. (US) 2006-04-20 WO disclosed